Biophan Announces Investor Conference Call at 12:00 pm Eastern Today

Business Wire, August 19, 2004

ROCHESTER, N.Y. -- President and CEO to Discuss Joint Development Agreement with NASA's Ames Research Center for Nanotechnology

Biophan Technologies, Inc. (OTCBB: BIPH), a leading developer of next generation biomedical technology, announced today that it will host an investor conference call today at 12:00 pm Eastern to discuss its agreement with NASA for characterization and joint development of high-density, nano-engineered thermoelectric materials for use with implantable medical devices. Research will be conducted at the NASA Ames Research Center for Nanotechnology, Moffett Field, CA.

The Company will discuss the impact and market opportunities represented by this joint development agreement on the conference call. Following the discussion, Michael Weiner, president and CEO of Biophan, will be available to answer questions regarding the technologies that may emerge from the partnership with the NASA Ames Research Center. Participants may ask questions during the Q & A segment of the call or, if they prefer, may e-mail questions in advance of the call to Michael Briola, executive vice president of Trilogy Capital Partners, michael@trilogy-capital.com.

To access the call, Investors should call 800-553-0351, or from an international location 612-332-0820, and request the "Biophan Conference Call." The discussion will also be webcast via streaming audio; to listen on the web, simply go to the Trilogy Capital Partners home page, at www.trilogy-capital.com, and click on the banner link for the conference call.

NASA hopes to use Biophan's innovative biothermal power solution to develop new on-board power for astronaut health monitors.

Biophan is developing new power systems for implantable medical devices using body heat to generate power. These are intended to replace or augment traditional power systems, such as lithium iodine batteries. By using the body's generation of heat as a power source, significantly longer life power systems are possible.

"The agreement with NASA highlights our commitment to collaborate with world-class development centers for commercializing the technologies that are part of Biophan's portfolio," stated Weiner. "With each new agreement, the viability of our research and that of our subsidiaries grows."

"We are pleased to be working with Biophan on a joint research initiative to help advance the concept of an implanted biothermal power source to power medical sensing and therapeutic devices," said David Lackner, technology partnership manager at NASA Ames Research Center. "On deep space missions, such as a trip to Mars, it's critical to have the efficient methods to monitor and treat astronauts."

Biophan recently acquired a majority interest in TE-Bio, developer of a patented innovation in thermoelectric materials using nanoscale-based, thin-film materials to convert body heat into electrical energy. The resulting power can be used to "trickle charge" batteries for medium-power devices such as defibrillators, or to directly power low-energy devices, such as pacemakers. These power systems have the potential to run for as long as 30 years-a five-fold increase in service life over existing technology-and thus may reduce the number of replacement implant medical procedures needed throughout a patient's life, reducing costs and potential complications.

News Announcement: Video

To view the online joint announcement from the NASA Ames Development Center at Moffett Field California, go to www.trilogy-capital.com.

About the NASA Ames Center for Nanotechnology

NASA Ames' nanotechnology effort started in early 1996 and has steadily grown to establish a Center for Nanotechnology. The research work focuses on experimental research and development in nano and biotechnologies as well as on a strong complementary modeling and simulation effort that includes computational nanotechnology, computational nanoelectronics, computational optoelectronics, and computational modeling of processes encountered in nanofabrication. The Center has about 55 scientists working on the above aspects; in addition, graduate students, faculty on sabbatical or summer visits, and undergraduate and high school students work at the Center through various internship programs.

The Center's vision is to develop novel concepts in nanotechnology for NASA's future needs on electronics, computing, sensors, and advanced miniaturization of all systems; and to develop highly integrated and intelligent simulation environment that facilitates the rapid development and validation of future generation electronic devices as well as associated materials and processes through virtual prototyping at multiple levels of fidelity. For more information, please visit www.ipt.arc.nasa.gov.

About Biophan Technologies

Biophan Technologies develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with magnetic resonance imaging (MRI) equipment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create enhanced MRI contrast agents. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 16 issued U.S. patents and 60 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, biothermal batteries, and photonics. Biophan's technology will help realize its goal of one day making all biomedical devices capable of safely and successfully working with MRI. For more information, please visit www.biophan.com.